search icon
      blog search icon

      BNOX Stock: A Deep Dive into the Pre-Market Stock Surge

      By Hasnain R

      Published on

      October 4, 2023

      9:22 AM UTC

      BNOX Stock: A Deep Dive into the Pre-Market Stock Surge

      The premarket session witnessed a significant surge in the stock of Bionomics Limited (BNOX), an Australian biotechnology firm focusing on the development of innovative, first-in-class, allosteric ion channel modulators for treating patients suffering from serious central nervous system (CNS) disorders.

      In the pre-market session today, Bionomics stock displayed remarkable performance, with its price surging to $3.90, reflecting an impressive change of 44.44%. This substantial uptick in price was accompanied by robust trading activity, as the trading volume reached 38,320,000 shares.

      These significant movements in the pre-market session have undoubtedly caught the attention of investors, signaling potential market excitement and anticipation for the trading day ahead.

      This article, an authoritative and detailed evaluation of the financial market, aims to provide a comprehensive understanding of the factors that contributed to the BNOX stock’s impressive performance.

      Key Financial Performance

      The financial performance of a US stocks usually significantly impacts their price. Bionomics Limited (BNOX) has recently reported a net loss of AU$31.8m, a 46% widening from FY 2022. Furthermore, the loss per share further deteriorated to AU$3.60 from AU$0.016 loss in FY 2022.

      Despite these figures, the company’s stock demonstrated a notable uptick. This can be attributed to several factors, including the company’s positive clinical trial results and the overall market trends.

      Clinical Trials and Drug Developments

      Phase 2b ATTUNE Clinical Trial

      The company recently announced positive top-line results from its Phase 2b ATTUNE Clinical Trial of BNC210 for the treatment of PTSD. This double-blind, placebo-controlled trial involved 212 patients from the United States and the United Kingdom.

      The primary endpoint of the trial was met, showing that BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity score at week 12.

      Phase II PREVAIL Study

      The company also reported full results from its Phase II PREVAIL study evaluating the efficacy and safety of two BNC210 doses for the acute treatment of SAD.

      Both doses of BNC210 resulted in reductions in anxiety across multiple phases of the public speaking challenge, demonstrating a favorable safety and tolerability profile.

      Stock Market Response

      Bionomics’ announcement of the successful clinical trial results triggered a massive surge in the company’s stock. During the previous trading session, Bionomics stock exhibited dynamic movements, with a previous close at $3.94 and a market capitalization of approximately $30.69 million. The trading volume for the day amounted to a substantial 28,605,187 shares.

      Relationship with Merck

      Bionomics has a collaboration with Merck, a leading global biopharmaceutical company. Merck is developing MK-4334, derived from Bionomics’ original α7 nAChR positive allosteric modulator (PAM) candidate, BNC375.

      Under the agreement, Merck funds all research, clinical development, and worldwide commercialization of any resulting products. Bionomics has received an upfront payment of $20 million and $10 million upon reaching a phase I milestone from Merck.

      It is eligible for up to $465 million in development and commercial milestone payments, plus royalties on net sales of licensed drugs. These collaborations effectively boost the financial strength of Bionomics and positively impact its stock value.

      Future Prospects

      Bionomics’ recent achievements have paved the way for promising future developments. The positive results from the Phase 2b ATTUNE study have positioned the company to discuss the registrational path for BNC210 in PTSD with the U.S. Food and Drug Administration (FDA).

      Furthermore, completion of the phase III-enabling End-of-phase II meeting with the FDA means BNC210 is ready to advance into registrational studies in the SAD indication.


      The surge in Bionomics stock is a testament to the potential of its drug-development endeavors and its strategic collaborations. The successful clinical trials and partnerships with pharmaceutical giants like Merck demonstrate Bionomics’ potential to emerge as a leading player in the biotechnology industry. The company’s future appears promising, and it will be interesting to see how US stocks respond to its upcoming endeavors.

      More From Stocks telegraph